Exploratory analysis finds neoadjuvant checkpoint blockade enhances pCR and DFS in high-risk patients, suggesting effectiveness in real-world settings.
It is possible to achieve a meaningful pCR rate and DFS by combining neoadjuvant checkpoint blockade with chemotherapy in patients with high-risk TNBC. Compared to clinical trials, however, there was a slightly lower pCR rate in this multicentered real-world study.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: